Condition
Nephrosis, Lipoid
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 4 (1)
Trial Status
Completed2
Terminated1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05797051Unknown
Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
NCT04387448Phase 2Terminated
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
NCT01185197Phase 4CompletedPrimary
Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study
NCT00577525CompletedPrimary
Latent Viral Infection of Lymphoid Cells in Idiopathic Nephrotic Syndrome
Showing all 4 trials